Madrigal Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−9.83%
vs ±10.5% implied · ×0.94
shaded = implied · ▲▼ = realized
Madrigal Pharmaceuticals has 7 disclosed suppliers and 1 disclosed customer in SEC filings.
Madrigal Pharmaceuticals, Inc.
433.06
SentenceIn May 2023, we entered into Amendment No. 1 (the "Sales Agreement Amendment") to our prior sales agreement (the "2021 Sales Agreement") with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC ("Cowen"), which was subsequently terminated in May 2024 when we entered into a Sales Agreement (the "2024 Sales Agreement") with Cowen, replacing and superseding the 2021 Sales Agreement, as amended by the Sales Agreement Amendment.
MDGL 10-Kaccession 0001628280-25-007980
SentenceIn July 2025, we entered into the CSPC License Agreement with CSPC for MGL-2086 (formerly known as SYH2086), an oral small molecule GLP-1 receptor agonist.
MDGL 10-Kaccession 0001628280-26-009514
Sentence10.51†# Resmetirom Commercial Supply Agreement, dated as of December 23, 2024, by and between Evonik Corporation and th e Registrant. Form 10-K (Exhibit 10.36) 2/26/2025 001-33277
MDGL 10-Kaccession 0001628280-26-009514
Sentence10.35†# Commercial Supply Agreement, dated as of August 21, 2023, by and between Gregory Pharmaceutical Holdings, In c. (d/b/a UPM Pharmaceuticals) and Madrigal Pharmaceuticals, Inc. X
MDGL 10-Kaccession 0001628280-25-007980
SentenceIn February 2026, we entered into the Ribocure License Agreement granting us exclusive global rights to develop, manufacture and commercialize six siRNA programs.
MDGL 10-Kaccession 0001628280-26-009514
SentenceUnder the Roche Agreement, Roche exclusively licensed certain patent rights and know-how relating to resmetirom in exchange for consideration consisting of an upfront payment, milestone payments tied to the achievement of product development and regulatory milestones, and royalty payments based on net sales of products containing resmetirom, including Rezdiffra, or another licensed product, subject to certain reductions.
MDGL 10-Kaccession 0001628280-25-007980
SentenceCustomer A 39 % — % — %
MDGL 10-Kaccession 0001628280-25-007980
Linked news
Expected move
Inputs8Q avg ±9.0%·×0.95·fair
straddle ±11.8%
spot 430.36exp Nov 20ATM strike 430ATM straddle 59.55IV 72%